The content is available as a PDF (314.9 KB).
References
- 1.Jacob AG, Driscoll DJ, Shaughnessv WJ, Stanson AW, Clay RP, Gloviczki P. Klippel-Trenaunay syndrome: Spectrum and management. Mayo Clini Proc. 1998;73:28–36. doi: 10.1016/S0025-6196(11)63615-X. [DOI] [PubMed] [Google Scholar]
- 2.Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovée JV. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015;166:1048–54. doi: 10.1016/j.jpeds.2014.12.069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kulungowski AM, Fox VL, Burrows PE, Alomari AI, Fishman SJ. Portomesenteric venous thrombosis associated with rectal venous malformations. J Pediatr Surg. 2010;45:1221–7. doi: 10.1016/j.jpedsurg.2010.02.092. [DOI] [PubMed] [Google Scholar]
- 4.Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, et al. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: A monocentric prospective phase II study. Orphanet J Rare Dis. 2018;13:191. doi: 10.1186/s13023-018-0934-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.di Blasio L, Puliafito A, Gagliardi PA, Comunanza V, Somale D, Chiaverina G. PI3K/mTOR inhibition pro motes the regression of experimental vascular malformations driven by PIK3CA-activating mutations. Cell Death Dis. 2018;9:45. doi: 10.1038/s41419-017-0064-x. [DOI] [PMC free article] [PubMed] [Google Scholar]